References
- Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36:995–7
- Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990;30:334–9
- Robbins L, Remmes A. Outpatient repetitive intravenous dihydroergotamine. Headache 1992;32:455–8
- Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache. 1995;35:177–84
- Gallagher RM. Acute treatment of migraine with dihydro-ergotamine nasal spray. Dihydroergotamine Working Group. Arch Neurol 1996;53:1285–91
- Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44:447–53
- Migranal [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals International; 2005
- Freitag FG, Lake A, 3rd, Lipton R, Cady R, Diamond S, Silberstein S. Inpatient treatment of headache: an evidence-based assessment. Headache 2004;44: 342–60
- Queiroz LP, Weeks RE, Rapoport AM, Sheftell FD, Baskin SM, Siegel SE. Early and transient side effects of repetitive intravenous dihydroergotamine. Headache 1996;36:291–4
- Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003;43:144–66
- Wang Y, Aun R, Tse FL. Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos 1998;19:571–5
- Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754–62
- Saper JR, Dodick D, Gladstone JP. Management of chronic daily headache: challenges in clinical practice. Headache 2005;45 Suppl 1:S74–85